49. Systemic lupus erythematosus Clinical trials / Disease details


Clinical trials : 946 Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01956188
(ClinicalTrials.gov)
May 201425/9/2013Omega 3 in LES and APSEfficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid SyndromeSystemic Lupus Erythematosus;Primary Antiphospholipid SyndromeDietary Supplement: EPA and DHA supplementation;Dietary Supplement: PlaceboUniversity of Sao PauloNULLActive, not recruiting20 Years45 YearsFemale22N/ABrazil
2EUCTR2005-000706-31-IT
(EUCTR)
15/09/200530/09/2005A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosusA Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients with Active Systemic LupusErythematosus improvement of signs and symptoms of Active Systemic Lupus Erythematosus
MedDRA version: 8.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus
Product Name: Epatuzumab
Product Code: hLL2,IMMU-103
IMMUNOMEDICSNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany;United Kingdom;Spain;Italy